石药巨石生物SYS6010启动II/III期临床 适应症为晚期/转移性食管鳞癌

新浪财经
Nov 14, 2025

药物临床试验登记与信息公示平台数据显示,石药集团巨石生物制药有限公司的评价SYS6010联合恩朗苏拜单抗注射液±5 - FU/卡培他滨治疗一线晚期/转移性食管鳞癌受试者的疗效和安全性的II/III期临床研究已启动。临床试验登记号为CTR20254287,首次公示信息日期为2025年11月13日。该试验药剂型包括注射用冻干粉针、注射液、片剂。SYS6010、恩朗苏拜单抗注射液、卡瑞利珠单抗、顺铂、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10